Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials

Bruce L. Davidson, H. R. Büller, H. Decousus, A. Gallus, M. Gent, F. Piovella, M. H. Prins, G. E. Raskob, A. E M Segers, A. W A Lensing

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Selecting initial anticoagulant dose by patient weight for acute pulmonary embolism and deep vein thrombosis has clinical credibility; however, uncertainty remains regarding how to dose obese patients with newer anticoagulants because outcome data are sparse. Objectives: To use the Matisse trials' comparison of sc fondaparinux once daily with control heparin therapies (intravenous unfractionated heparin for pulmonary embolism, sc enoxaparin 1mg/kg b.i.d. for deep vein thrombosis) for initial treatment in order to compare primary outcomes (venous thromboembolism recurrence and major bleeding) in obese patients. Patients and methods: Primary outcomes were compared in subsets composed of patients weighing ≤ and > 100kg and with body mass index (BMI) <30 and ≥ 30kg/m2. Medians and ranges for weight and BMI were compared for patients suffering either recurrence or major bleeding. Results: Twenty-two thousand and one patients received fondaparinux and 2217 received enoxaparin or unfractionated heparin. Four hundred and ninety-six patients (11%) weighed > 100kg and 1216 (28%) had a BMI ≥ 30. Treatment groups had similar characteristics. The upper limit in subject weight for recurrence was 166kg (BMI 58), and for major bleeding 120kg (BMI 39). The incidences of recurrence and major bleeding were similar for each patient subset of weight and BMI for both fondaparinux and heparin treatment groups. Among patients with a primary outcome, median weights and BMIs were also similar. Conclusions: The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients.

Original languageEnglish
Pages (from-to)1191-1194
Number of pages4
JournalJournal of Thrombosis and Haemostasis
Volume5
Issue number6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Enoxaparin
Venous Thromboembolism
Heparin
Obesity
Body Mass Index
Hemorrhage
Weights and Measures
Recurrence
Therapeutics
Pulmonary Embolism
Venous Thrombosis
Anticoagulants
fondaparinux
Uncertainty
Incidence

Keywords

  • Body mass index
  • Fondaparinux
  • Heparin
  • Low-molecular-weight heparin
  • Obesity
  • Venous thromboembolism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. / Davidson, Bruce L.; Büller, H. R.; Decousus, H.; Gallus, A.; Gent, M.; Piovella, F.; Prins, M. H.; Raskob, G. E.; Segers, A. E M; Lensing, A. W A.

In: Journal of Thrombosis and Haemostasis, Vol. 5, No. 6, 06.2007, p. 1191-1194.

Research output: Contribution to journalArticle

Davidson, Bruce L. ; Büller, H. R. ; Decousus, H. ; Gallus, A. ; Gent, M. ; Piovella, F. ; Prins, M. H. ; Raskob, G. E. ; Segers, A. E M ; Lensing, A. W A. / Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. In: Journal of Thrombosis and Haemostasis. 2007 ; Vol. 5, No. 6. pp. 1191-1194.
@article{90585df7e93647c8a1290a6b57860682,
title = "Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials",
abstract = "Background: Selecting initial anticoagulant dose by patient weight for acute pulmonary embolism and deep vein thrombosis has clinical credibility; however, uncertainty remains regarding how to dose obese patients with newer anticoagulants because outcome data are sparse. Objectives: To use the Matisse trials' comparison of sc fondaparinux once daily with control heparin therapies (intravenous unfractionated heparin for pulmonary embolism, sc enoxaparin 1mg/kg b.i.d. for deep vein thrombosis) for initial treatment in order to compare primary outcomes (venous thromboembolism recurrence and major bleeding) in obese patients. Patients and methods: Primary outcomes were compared in subsets composed of patients weighing ≤ and > 100kg and with body mass index (BMI) <30 and ≥ 30kg/m2. Medians and ranges for weight and BMI were compared for patients suffering either recurrence or major bleeding. Results: Twenty-two thousand and one patients received fondaparinux and 2217 received enoxaparin or unfractionated heparin. Four hundred and ninety-six patients (11{\%}) weighed > 100kg and 1216 (28{\%}) had a BMI ≥ 30. Treatment groups had similar characteristics. The upper limit in subject weight for recurrence was 166kg (BMI 58), and for major bleeding 120kg (BMI 39). The incidences of recurrence and major bleeding were similar for each patient subset of weight and BMI for both fondaparinux and heparin treatment groups. Among patients with a primary outcome, median weights and BMIs were also similar. Conclusions: The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients.",
keywords = "Body mass index, Fondaparinux, Heparin, Low-molecular-weight heparin, Obesity, Venous thromboembolism",
author = "Davidson, {Bruce L.} and B{\"u}ller, {H. R.} and H. Decousus and A. Gallus and M. Gent and F. Piovella and Prins, {M. H.} and Raskob, {G. E.} and Segers, {A. E M} and Lensing, {A. W A}",
year = "2007",
month = "6",
doi = "10.1111/j.1538-7836.2007.02565.x",
language = "English",
volume = "5",
pages = "1191--1194",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials

AU - Davidson, Bruce L.

AU - Büller, H. R.

AU - Decousus, H.

AU - Gallus, A.

AU - Gent, M.

AU - Piovella, F.

AU - Prins, M. H.

AU - Raskob, G. E.

AU - Segers, A. E M

AU - Lensing, A. W A

PY - 2007/6

Y1 - 2007/6

N2 - Background: Selecting initial anticoagulant dose by patient weight for acute pulmonary embolism and deep vein thrombosis has clinical credibility; however, uncertainty remains regarding how to dose obese patients with newer anticoagulants because outcome data are sparse. Objectives: To use the Matisse trials' comparison of sc fondaparinux once daily with control heparin therapies (intravenous unfractionated heparin for pulmonary embolism, sc enoxaparin 1mg/kg b.i.d. for deep vein thrombosis) for initial treatment in order to compare primary outcomes (venous thromboembolism recurrence and major bleeding) in obese patients. Patients and methods: Primary outcomes were compared in subsets composed of patients weighing ≤ and > 100kg and with body mass index (BMI) <30 and ≥ 30kg/m2. Medians and ranges for weight and BMI were compared for patients suffering either recurrence or major bleeding. Results: Twenty-two thousand and one patients received fondaparinux and 2217 received enoxaparin or unfractionated heparin. Four hundred and ninety-six patients (11%) weighed > 100kg and 1216 (28%) had a BMI ≥ 30. Treatment groups had similar characteristics. The upper limit in subject weight for recurrence was 166kg (BMI 58), and for major bleeding 120kg (BMI 39). The incidences of recurrence and major bleeding were similar for each patient subset of weight and BMI for both fondaparinux and heparin treatment groups. Among patients with a primary outcome, median weights and BMIs were also similar. Conclusions: The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients.

AB - Background: Selecting initial anticoagulant dose by patient weight for acute pulmonary embolism and deep vein thrombosis has clinical credibility; however, uncertainty remains regarding how to dose obese patients with newer anticoagulants because outcome data are sparse. Objectives: To use the Matisse trials' comparison of sc fondaparinux once daily with control heparin therapies (intravenous unfractionated heparin for pulmonary embolism, sc enoxaparin 1mg/kg b.i.d. for deep vein thrombosis) for initial treatment in order to compare primary outcomes (venous thromboembolism recurrence and major bleeding) in obese patients. Patients and methods: Primary outcomes were compared in subsets composed of patients weighing ≤ and > 100kg and with body mass index (BMI) <30 and ≥ 30kg/m2. Medians and ranges for weight and BMI were compared for patients suffering either recurrence or major bleeding. Results: Twenty-two thousand and one patients received fondaparinux and 2217 received enoxaparin or unfractionated heparin. Four hundred and ninety-six patients (11%) weighed > 100kg and 1216 (28%) had a BMI ≥ 30. Treatment groups had similar characteristics. The upper limit in subject weight for recurrence was 166kg (BMI 58), and for major bleeding 120kg (BMI 39). The incidences of recurrence and major bleeding were similar for each patient subset of weight and BMI for both fondaparinux and heparin treatment groups. Among patients with a primary outcome, median weights and BMIs were also similar. Conclusions: The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients.

KW - Body mass index

KW - Fondaparinux

KW - Heparin

KW - Low-molecular-weight heparin

KW - Obesity

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=34250191498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250191498&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2007.02565.x

DO - 10.1111/j.1538-7836.2007.02565.x

M3 - Article

C2 - 17403087

AN - SCOPUS:34250191498

VL - 5

SP - 1191

EP - 1194

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 6

ER -